GC Biopharma reported preliminary Q3 2026 results (consolidated): Revenue of KRW 522.1 billion (-14.3% year over year), operating profit of KRW 49.2 billion (+68.5% year over year), net profit of KRW 208.5 billion (+1051.9% year over year).

Preliminary EarningsFiled Nov 2, 2026

Unofficial English translation by ChickenStock; the Korean original prevails. Korean page · Original filing on DART ↗

Highlights

Structured data

Written in code from the structured data of the filing. Reference information, not investment advice.

Key figures

Period: Q3 2026
Basis: Consolidated
Revenue: KRW 522.1 billion (-14.3% year over year)
Operating profit: KRW 49.2 billion (+68.5% year over year)
Net profit: KRW 208.5 billion (+1051.9% year over year)

Filing facts

Filing type: Preliminary Earnings
Report name: Preliminary Consolidated Operating Results (Fair Disclosure)
Filed: Nov 2, 2026
Receipt number: 20261102800193

GC Biopharma stock page →Korean page →Original filing on DART ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.